Evidence mapPaperPMID 31496499Full record

ArticleThe Permanente journal2019

Statin-Associated Cardiomyopathy Responds to Statin Withdrawal and Administration of Coenzyme Q

Peter H Langsjoen, Jens O Langsjoen, Alena M Langsjoen, Franklin Rosenfeldt

Open access · greenAbstract read
In one paragraph

Article in The Permanente journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Biosynthesis, Deficiency, and Supplementation of Coenzyme Q.Antioxidants (Basel, Switzerland) · 2023
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Peter H LangsjoenPeter H Langsjoen, MD, PA, Tyler, TX.
Jens O LangsjoenDepartment of Internal Medicine, University of New Mexico, Albuquerque.
Alena M LangsjoenPeter H Langsjoen, MD, PA, Tyler, TX.
Franklin RosenfeldtBaker IDI Heart and Disease Institute, Melbourne, Australia.
Swinburne University of Technology · AUUniversity of New Mexico · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextHeart failure (HF) is rapidly increasing in incidence and is often present in patients receiving long-term statin therapy.

objectiveTo test whether or not patients with HF on long-term statin therapy respond to discontinuation of statin therapy and initiation of coenzyme Q

designWe prospectively identified patients receiving long-term statin therapy in whom HF developed in the absence of any identifiable cause. Treatment consisted of simultaneous statin therapy discontinuation and CoQ

main outcome measuresBaseline and follow-up physical examination findings, symptom scores, echocardiograms, and plasma CoQ

resultsOf 142 identified patients with HF, 94% presented with preserved ejection fraction (EF) and 6% presented with reduced EF (< 50%). After a mean follow-up of 2.8 years, New York Heart Association class 1 increased from 8% to 79% (p < 0.0001). In patients with preserved EF, 34% had normalization of diastolic function and 25% showed improvement (p < 0.0001). In patients with reduced EF at baseline, the EF improved from a mean of 35% to 47% (p = 0.02). Statin-attributable symptoms including fatigue, muscle weakness, myalgias, memory loss, and peripheral neuropathy improved (p < 0.01). The 1-year mortality was 0%, and the 3-year mortality was 3%.

conclusionIn patients receiving long-term statin therapy, statin-associated cardiomyopathy may develop that responds safely to statin treatment discontinuation and CoQ

Indexed as

AgedCardiomyopathiesCholesterolFemaleHeart FailureHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleStroke VolumeUbiquinoneVitamin ECholesterolcoenzyme Q10Hydroxymethylglutaryl-CoA Reductase InhibitorsUbiquinoneVitamin E

Identifiers

PMID31496499
PMCPMC6730959
OpenAlexW2981260345

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.